The Safety and Effectiveness of Indinavir Sulfate Plus Efavirenz
- Conditions
- HIV Infections
- Registration Number
- NCT00002387
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
To estimate the differences in parameters of antiviral activity and safety between a control regimen of indinavir in combination with DMP 266 and an experimental regimen of higher-dose indinavir in combination with lower-dose DMP 266 after sixteen weeks of dosing, in protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-naive, HIV-1 seropositive patients.
It is hypothesized that after 16 weeks of randomized treatment with either the control or experimental regimen that:
1. The observed proportion of patients with serum viral RNA \< 400 copies/ml in the experimental and control regimen will be similar and will continue to be so after 48 weeks.
2. The safety profiles of the two groups will be similar, judged by the incidence of serious, drug-related adverse experiences and the incidence of events of specific interest (e.g., nephrolithiasis, hyperbilirubinemia, nausea/vomiting, rash, and CNS-related symptoms) and will continue to be so after 48 weeks.
3. The two groups will be similar with respect to changes from baseline in serum viral RNA and CD4 counts and will continue to be so after 48 weeks.
- Detailed Description
It is hypothesized that after 16 weeks of randomized treatment with either the control or experimental regimen that:
1. The observed proportion of patients with serum viral RNA \< 400 copies/ml in the experimental and control regimen will be similar and will continue to be so after 48 weeks.
2. The safety profiles of the two groups will be similar, judged by the incidence of serious, drug-related adverse experiences and the incidence of events of specific interest (e.g., nephrolithiasis, hyperbilirubinemia, nausea/vomiting, rash, and CNS-related symptoms) and will continue to be so after 48 weeks.
3. The two groups will be similar with respect to changes from baseline in serum viral RNA and CD4 counts and will continue to be so after 48 weeks.
Patients are randomized to one of two regimens: a control regimen of indinavir plus DMP 266 or an experimental regimen of indinavir plus DMP 266, each at different doses than in the control regimen.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 80
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (8)
San Francisco Gen Hosp
🇺🇸San Francisco, California, United States
Brown Univ / Miriam Hosp
🇺🇸Providence, Rhode Island, United States
Rush Med Ctr / Section of Infectious Diseases
🇺🇸Chicago, Illinois, United States
Univ Hosp / SUNY at Stony Brook / AIDS TMT Unit
🇺🇸Stony Brook, New York, United States
UCSD Treatment Ctr / Dept of Medicine & Pediatrics
🇺🇸San Diego, California, United States
Hawaii AIDS Clinical Trial Unit
🇺🇸Honolulu, Hawaii, United States
Univ of Colorado / Health Science Ctr
🇺🇸Denver, Colorado, United States
Beth Israel Hosp
🇺🇸Boston, Massachusetts, United States